Uptake of co-testing with HPV and cytology for cervical screening: A population-based evaluation in the United States

•Cervical cancer screening by co-testing increased from 5.6% in 2008 to 84.3% in 2019 among women ages 30–64 years.•Smaller increases in co-test usage were observed in women of younger ages, although not currently recommended.•The median screening interval increased from 15 to 39 months as screening guideline recommendations were adopted.•The near exclusive use of the Hybrid Capture II HPV test has changed to the use of target amplified HPV tests.